Level 3 - Budget & Vendor Evaluation

At this stage, biotech teams often ask:

• Why are CRO proposals coming back with wide budget ranges and inconsistent assumptions?

• Why line items feel difficult to compare across vendors?

• Do these cost differences reflect scope, geography, or hidden risk buffers?

• Is the business development narrative stronger than the operational clarity behind it?

• Are promised oversight levels aligned with the actual execution model?

• Have we foreseen potential change orders?

• Are we feeling pressure to move forward before full financial and contractual visibility is achieved?

• Are our internal discussions drifting toward urgency rather than disciplined comparison?

Is this stage familiar?

Proposal & Budget Architecture

• Line-by-line proposal structure review

• Budget benchmarking & Fair Market Value

• Scope alignment vs protocol intent

• Assumptions embedded in cost calculations

• Change order exposure analysis

Vendor Capability Assessment & Operational Fit

• CRO operational model alignment

• Therapeutic and geographic suitability

• Resourcing assumptions

• Oversight burden implications

Clinical & Protocol Alignment Validation

• Proposal consistency with development strategy

• Operational feasibility of protocol design

• Hidden scope expansion risks

What We Evaluate

Financial & Contractual Risk Assessment

• Budget structure sustainability

• Milestone and payment logic review

• Liability and risk allocation assessment

• Contractual red flag identification

Negotiation Positioning & Governance Boundaries

• Definition of negotiation boundaries and non-negotiable, concession priorities and trade-off logic to protect strategic & financial positioning

• Budget negotiation strategy & internal escalation pathways during negotation

• Bid defense preparation & alignment

Evaluation of the company situation across five dimensions:

What You Receive

RFP Review & Proposal Comparison Report

Structured comparative analysis of vendor proposals highlighting financial, operational, and contractual differences.

Budget Negotiation Strategy

Strategic guidance during financial negotiation to protect capital allocation and long-term flexibility.

Bid Defense Strategy

Independent preparation and evaluation to strengthen internal positioning during vendor presentations.

Contractual & Financial Risk Red Flag Summary

Clear identification of structural risk exposure prior to final vendor selection.

Executive CRO Decision Brief

A structured executive-level report consolidating:

• Comparative vendor assessment

• Budget benchmarking insights

• Key contractual and financial observations

• Negotiation boundary map

• Clear recommendation rationale

Designed for internal leadership and investor-facing clarity. A decision-ready synthesis before contractual commitment.

Level 3 ensures vendor selection is not driven by urgency or presentation quality, but by protecting your capital allocation at the exact moment it matters most.

Engagement scope and investment vary depending on trial complexity and stage. All collaborations begin with a structured exploratory discussion.